207 related articles for article (PubMed ID: 32816899)
1. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
[TBL] [Abstract][Full Text] [Related]
2. Maximizing Regulatory Review Efficiency: The Evolution of the FDA OCE RTOR Pilot.
Gao YG; Roberts S; Guy A
Ther Innov Regul Sci; 2022 Mar; 56(2):212-219. PubMed ID: 35006588
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities.
Feng C; Virparia R; Mui ET
Ther Innov Regul Sci; 2021 Jul; 55(4):881-888. PubMed ID: 33913098
[TBL] [Abstract][Full Text] [Related]
4. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.
Arora S; Narayan P; Osgood CL; Wedam S; Prowell TM; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Ghosh S; Philip R; Ison G; Berman T; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1072-1086. PubMed ID: 34711632
[TBL] [Abstract][Full Text] [Related]
5. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
[TBL] [Abstract][Full Text] [Related]
6. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
7. Overview of Oncology and Hematology Drug Approvals at US Food and Drug Administration Between 2008 and 2016.
Zhou J; Vallejo J; Kluetz P; Pazdur R; Kim T; Keegan P; Farrell A; Beaver JA; Sridhara R
J Natl Cancer Inst; 2019 May; 111(5):449-458. PubMed ID: 30085269
[TBL] [Abstract][Full Text] [Related]
8. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
9. FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
Kluetz PG; Keegan P; Demetri GD; Thornton K; Sul J; Kim J; Katzen H; Burke LB; Harvey RD; Alebachew E; Agrawal S; Nair A; Donoghue M; Pierce WF; Shord SS; Gao JJ; Pazdur R
Clin Cancer Res; 2021 Feb; 27(4):916-921. PubMed ID: 33257426
[TBL] [Abstract][Full Text] [Related]
10. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.
Arora S; Narayan P; Ison G; Berman T; Suzman DL; Wedam S; Prowell TM; Ghosh S; Philip R; Osgood CL; Gao JJ; Shah M; Krol D; Wahby S; Royce M; Brus C; Bloomquist EW; Fiero MH; Tang S; Pazdur R; Ibrahim A; Amiri-Kordestani L; Beaver JA
Clin Cancer Res; 2022 Mar; 28(6):1058-1071. PubMed ID: 34711631
[TBL] [Abstract][Full Text] [Related]
11. Project Orbis: Global Collaborative Review Program.
de Claro RA; Spillman D; Hotaki LT; Shum M; Mouawad LS; Santos GML; Robinson K; Hunt M; Healy C; Chan A; Looi YH; Rodrigues C; Rohr UP; Walther C; Pazdur R
Clin Cancer Res; 2020 Dec; 26(24):6412-6416. PubMed ID: 33037016
[TBL] [Abstract][Full Text] [Related]
12. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
13. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
Mooghali M; Mohammad A; Wallach JD; Mitchell AP; Ross JS; Ramachandran R
JAMA Netw Open; 2024 May; 7(5):e249233. PubMed ID: 38691363
[TBL] [Abstract][Full Text] [Related]
14. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
[TBL] [Abstract][Full Text] [Related]
15. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
16. Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
Arondekar B; Duh MS; Bhak RH; DerSarkissian M; Huynh L; Wang K; Wojciehowski J; Wu M; Wornson B; Niyazov A; Demetri GD
Clin Cancer Res; 2022 Jan; 28(1):27-35. PubMed ID: 34667027
[TBL] [Abstract][Full Text] [Related]
17. Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid.
Algorri M; Acharya A; Bernstein J; Cauchon NS; Chen XH; Huynh-Ba K; Krantz C; Li T; Li Y; McLamore S; Roberts SW; Schwinke D; Shah R; Schirmer A; Strickland H; Tang K; Watson T
AAPS Open; 2022; 8(1):19. PubMed ID: 36530577
[TBL] [Abstract][Full Text] [Related]
18. Loose Regulatory Standards Portend a New Era of Imprecision Oncology.
Khaki AR
Cancer Invest; 2021 Feb; 39(2):120-123. PubMed ID: 33290099
[TBL] [Abstract][Full Text] [Related]
19. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
20. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
